Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
An expert discusses how comprehensive genomic profiling panels that include relevant targets, resistance markers, and clonal hematopoiesis information have proven most useful, along with technologies that can detect fusion events, point mutations, and copy number variations for serial monitoring over time.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
Video content above is prompted by the following:
In his practice, Hatim Husain, MD, utilizes comprehensive genomic profiling panels that include all relevant genomic targets, including resistance markers, to guide treatment decisions effectively. These technologies provide crucial information about clonal hematopoiesis, particularly important in liquid biopsies where genomic alterations in plasma may originate from white blood cells rather than tumor tissue. Advanced platforms offer frameworks to distinguish tumor-derived alterations from those originating in leukocytes, enhancing diagnostic accuracy.
The discussion emphasizes the importance of technologies capable of detecting fusion events, point mutations, and copy number variations. Copy number alterations are increasingly recognized as important factors in understanding driver events vs resistance profiles in lung cancer. Some therapeutic approvals are now based on copy number variations, highlighting the clinical relevance of comprehensive genomic analysis beyond traditional mutation detection.
Technologies enabling serial testing to provide qualitative information about genomic changes over time, offering insights into resistance development and tumor burden evolution. These capabilities allow clinicians to monitor how the genome changes throughout treatment, correlate molecular findings with imaging results like CT scans, and understand resistance mechanisms. This temporal genomic monitoring represents an emerging paradigm in precision oncology, integrating advanced cancer genomics with current treatment approaches.
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
